A NEW WORD IN LUNG CANCER TREATMENTSupporting Arguments
• The results of the Phase 2 trials of taletrectinib are expected to be presented at the ESMO Congress.
• The technical outlook for NUVB appears favorable.
Investment Thesis
Nuvation Bio (NUVB) is a biopharmaceutical company dedicated to addressing unmet needs in oncology